checkAd

    DGAP-News  582  0 Kommentare PAION SUCCESSFULLY COMPLETES PATIENT RECRUITMENT IN U.S. PHASE III STUDY WITH REMIMAZOLAM FOR PROCEDURAL SEDATION DURING BRONCHOSCOPY - Seite 4





     











    28.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de




























    Language: English
    Company: PAION AG
    Martinstr. 10-12
    52062 Aachen
    Germany
    Phone: +49 (0)241-4453-0
    Fax: +49 (0)241-4453-100
    E-mail: info@paion.com
    Internet: www.paion.com
    ISIN: DE000A0B65S3
    WKN: A0B65S
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange





     
    End of News DGAP News Service


    Lesen Sie auch



    558189  28.03.2017 




    Seite 4 von 4



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DGAP-News PAION SUCCESSFULLY COMPLETES PATIENT RECRUITMENT IN U.S. PHASE III STUDY WITH REMIMAZOLAM FOR PROCEDURAL SEDATION DURING BRONCHOSCOPY - Seite 4 DGAP-News: PAION AG / Key word(s): Research Update PAION SUCCESSFULLY COMPLETES PATIENT RECRUITMENT IN U.S. PHASE III STUDY WITH REMIMAZOLAM FOR PROCEDURAL SEDATION DURING BRONCHOSCOPY 28.03.2017 / 07:30 The issuer is solely responsible for the …